224 related articles for article (PubMed ID: 20190467)
1. Response of serum carboxylated and undercarboxylated osteocalcin to risedronate monotherapy and combined therapy with vitamin K(2) in corticosteroid-treated patients: a pilot study.
Hozuki T; Imai T; Tsuda E; Matsumura A; Yamamoto D; Toyoshima T; Suzuki S; Yamauchi R; Hayashi T; Hisahara S; Shimohama S
Intern Med; 2010; 49(5):371-6. PubMed ID: 20190467
[TBL] [Abstract][Full Text] [Related]
2. Effects of risedronate alone or combined with vitamin K2 on serum undercarboxylated osteocalcin and osteocalcin levels in postmenopausal osteoporosis.
Kasukawa Y; Miyakoshi N; Ebina T; Aizawa T; Hongo M; Nozaka K; Ishikawa Y; Saito H; Chida S; Shimada Y
J Bone Miner Metab; 2014 May; 32(3):290-7. PubMed ID: 23846118
[TBL] [Abstract][Full Text] [Related]
3. Additive effect of vitamin K2 and risedronate on long bone mass in hypophysectomized young rats.
Iwamoto J; Takeda T; Sato Y; Yeh JK
Exp Anim; 2007 Apr; 56(2):103-10. PubMed ID: 17460355
[TBL] [Abstract][Full Text] [Related]
4. The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study.
Dundar U; Kavuncu V; Ciftci IH; Evcik D; Solak O; Cakir T
J Bone Miner Metab; 2009; 27(4):464-70. PubMed ID: 19301089
[TBL] [Abstract][Full Text] [Related]
5. Beneficial effect of pretreatment and treatment continuation with risedronate and vitamin K2 on cancellous bone loss after ovariectomy in rats: a bone histomorphometry study.
Iwamoto J; Takeda T; Sato Y; Shen CL; Yeh JK
J Nutr Sci Vitaminol (Tokyo); 2006 Oct; 52(5):307-15. PubMed ID: 17190100
[TBL] [Abstract][Full Text] [Related]
6. Design of a randomized clinical trial of concurrent treatment with vitamin K2 and risedronate compared to risedronate alone in osteoporotic patients: Japanese Osteoporosis Intervention Trial-03 (JOINT-03).
Tanaka S; Miyazaki T; Uemura Y; Kuroda T; Miyakawa N; Nakamura T; Fukunaga M; Ohashi Y; Ohta H; Mori S; Hagino H; Hosoi T; Sugimoto T; Itoi E; Orimo H; Shiraki M
J Bone Miner Metab; 2014 May; 32(3):298-304. PubMed ID: 23828145
[TBL] [Abstract][Full Text] [Related]
7. Monitoring of Risedronate by biochemical bone markers in clinical practice.
Bunyaratavej N
J Med Assoc Thai; 2005 Oct; 88(suppl 5):S34-6. PubMed ID: 17500121
[TBL] [Abstract][Full Text] [Related]
8. Osteoclast inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results.
Morishita M; Nagashima M; Wauke K; Takahashi H; Takenouchi K
J Rheumatol; 2008 Mar; 35(3):407-13. PubMed ID: 18260178
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of risedronate in Japanese male patients with primary osteoporosis.
Majima T; Shimatsu A; Komatsu Y; Satoh N; Fukao A; Ninomiya K; Matsumura T; Nakao K
Intern Med; 2008; 47(8):717-23. PubMed ID: 18421187
[TBL] [Abstract][Full Text] [Related]
10. Response of serum carboxylated and undercarboxylated osteocalcin to alendronate monotherapy and combined therapy with vitamin K2 in postmenopausal women.
Hirao M; Hashimoto J; Ando W; Ono T; Yoshikawa H
J Bone Miner Metab; 2008; 26(3):260-4. PubMed ID: 18470667
[TBL] [Abstract][Full Text] [Related]
11. Effect of risedronate on high-dose corticosteroid-induced bone loss in patients with glomerular disease.
Kikuchi Y; Imakiire T; Yamada M; Saigusa T; Hyodo T; Kushiyama T; Higashi K; Hyodo N; Yamamoto K; Suzuki S; Miura S
Nephrol Dial Transplant; 2007 Jun; 22(6):1593-600. PubMed ID: 17041001
[TBL] [Abstract][Full Text] [Related]
12. The prevention of hip fracture with menatetrenone and risedronate plus calcium supplementation in elderly patients with Alzheimer disease: a randomized controlled trial.
Sato Y; Honda Y; Umeno K; Hayashida N; Iwamoto J; Takeda T; Matsumoto H
Kurume Med J; 2011; 57(4):117-24. PubMed ID: 21778673
[TBL] [Abstract][Full Text] [Related]
13. High level of serum undercarboxylated osteocalcin in patients with incident fractures during bisphosphonate treatment.
Shiraki M; Yamazaki Y; Shiraki Y; Hosoi T; Tsugawa N; Okano T
J Bone Miner Metab; 2010 Sep; 28(5):578-84. PubMed ID: 20221651
[TBL] [Abstract][Full Text] [Related]
14. Clinical results of alendronate monotherapy and combined therapy with menatetrenone (VitK₂) in postmenopausal RA patients.
Suzuki K; Tsuji S; Fukushima Y; Nakase T; Hamada M; Tomita T; Yoshikawa H
Mod Rheumatol; 2013 May; 23(3):450-5. PubMed ID: 22692649
[TBL] [Abstract][Full Text] [Related]
15. Effect of low dose vitamin K2 (MK-4) supplementation on bio-indices in postmenopausal Japanese women.
Koitaya N; Ezaki J; Nishimuta M; Yamauchi J; Hashizume E; Morishita K; Miyachi M; Sasaki S; Ishimi Y
J Nutr Sci Vitaminol (Tokyo); 2009 Feb; 55(1):15-21. PubMed ID: 19352059
[TBL] [Abstract][Full Text] [Related]
16. The effect of risedronate treatment on serum osteoprotegerin and bone marker levels in postmenopausal women with osteoporosis.
Karadag-Saygi E; Akyuz G; Bizargity P; Ay P
Gynecol Endocrinol; 2011 Dec; 27(12):1033-6. PubMed ID: 21627558
[TBL] [Abstract][Full Text] [Related]
17. Nutritional Therapy with Vitamin K
Kuwabara A; Nagae A; Kitagawa M; Tozawa K; Kumode M; Tanaka K
J Nutr Sci Vitaminol (Tokyo); 2020; 66(3):278-284. PubMed ID: 32612091
[TBL] [Abstract][Full Text] [Related]
18. Vitamin K nutritional status and undercarboxylated osteocalcin in postmenopausal osteoporotic women treated with bisphosphonates.
Iwamoto J; Takada T; Sato Y
Asia Pac J Clin Nutr; 2014; 23(2):256-62. PubMed ID: 24901095
[TBL] [Abstract][Full Text] [Related]
19. Serum NTX is a practical marker for assessing antiresorptive therapy for glucocorticoid treated patients with chronic kidney disease.
Hamano T; Fujii N; Nagasawa Y; Isaka Y; Moriyama T; Okada N; Imai E; Horio M; Ito T
Bone; 2006 Nov; 39(5):1067-1072. PubMed ID: 16781904
[TBL] [Abstract][Full Text] [Related]
20. Effect of vitamin K2 treatment on carboxylation of osteocalcin in early postmenopausal women.
Yasui T; Miyatani Y; Tomita J; Yamada M; Uemura H; Miura M; Irahara M
Gynecol Endocrinol; 2006 Aug; 22(8):455-9. PubMed ID: 17012108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
